International Society

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Retrieved on: 
Monday, March 4, 2024
Paper, Comparison, Algorithm, PD, ACON, Gold standard, Physician, Pain, Surgeon, Discography, International Society, Biomarker, Software as a service, CLARITY, Patient, Canadian International Council, Diagnosis, Low back pain, CO, Research, Medical imaging

BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the publication of the clinical paper, Establishing a Gold Standard for Noninvasive Identification of Painful Lumbar Discs: Prospective Comparison of Magnetic Resonance Spectroscopy vs Low-Pressure Provocation Discography by the International Journal of Spine Surgery, the official scientific journal of the International Society for the Advancement of Spine Surgery (ISASS).

Key Points: 
  • Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons.
  • Low-pressure provocative discography (PD) has served as the gold standard, despite well-documented drawbacks including being highly invasive and presenting difficult-to-interpret results.
  • Achieving a result of 100% sensitivity (5/5 lumbar discs) means that in this study if discography indicates a disc is painful, then Nociscan will also indicate that the disc is painful.
  • We look forward to introducing Nociscan to a growing number of physicians and patients.”
    Access to the publication can be found here.

Catalight Unveils Wellbeing Scale to Assess and Enhance the Lives of Families Living with Intellectual Developmental Disabilities and Autism

Retrieved on: 
Thursday, February 29, 2024
BCBA, Organization, Family, Youth, International Society, Disability studies, Medicine, Clinical, Happiness, Journal, Data analysis, Marriage, DSM-IV codes, Clutch (eggs), Spectrum, Research, Psychometrics, Nursing

For more than a decade, Catalight has sought to define wellbeing as not just a nebulous, variable feeling but as a measure of treatment success.

Key Points: 
  • For more than a decade, Catalight has sought to define wellbeing as not just a nebulous, variable feeling but as a measure of treatment success.
  • In serving clients with I/DD and autism, clinicians utilize various strategies to improve the lives of the individual and their families, decrease stress and save time.
  • The scale itself and its subsequent psychometrics turned heads at the International Society for Autism Research annual meeting last year in Stockholm, Sweden.
  • By considering a broad range of factors, the scale provides a more comprehensive and nuanced understanding of family wellbeing.

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, February 29, 2024
Acquisition, Research, Reiterate, Neoplasm, FDA, Cancer, Adium, Disassembler, International Society, NASDAQ Biotechnology Index, Interim, GM-CSF, Self-assembly, NBI, Therapy, Interest, Patient, HITS, Clinical trial, Congress, IND, Human, Cryptocurrency

On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.

Key Points: 
  • On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.
  • The DANYELZA net product revenues of $23.4 million in the fourth quarter of 2023, represented a favorable 17% increase compared to the third quarter of 2023, primarily driven by increased U.S. sales.
  • The Company did not have license revenues in the quarter ended December 31, 2023 and had license revenues of $0.5 million for the year ended December 31, 2023.
  • The net income for the quarter ended December 31, 2022, was after $15.0 million of license revenue recognized in the fourth quarter of 2022.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Wednesday, February 28, 2024
NSCLC, Research, Gene, GSK, TIL, SITC, Growth, AP-1 transcription factor, Cell, International Society, NR4A3, Annual general meeting, Lung cancer, Society, Triple-negative breast cancer, GAAP, Biomarker, Phenotype, TNBC, Patient, Organization, Survival, TCR, Lyell, GSK plc, ISSCR, G&A, Literature, Workforce, IND, Corporation, Colorectal cancer, Vaccine

The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).

Key Points: 
  • The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).
  • The increase in fourth quarter 2023 non-GAAP R&D expenses was driven by an increase in research and laboratory costs primarily associated with clinical trials.
  • The decrease in both fourth quarter 2023 and annual 2023 G&A expenses were both primarily driven by decreases in non-cash stock-based compensation.
  • The decrease in 2023 non-GAAP G&A expenses was driven by a decrease in legal and corporate expenses.

PharmAla named an Intellectual Property Ontario Client

Retrieved on: 
Thursday, February 22, 2024
MDXX, Research, IPON, ABA, Education, OTC, Work, Drug development, International Society, ACS Chemical Neuroscience, MDMA, University, Intellectual property, IP, Pharmaceutical industry

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) announces today that it has been accepted as a client of Intellectual Property Ontario (IPON).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) announces today that it has been accepted as a client of Intellectual Property Ontario (IPON).
  • PharmAla is further pleased to note that IPON has approved its initial Scope of Work pertaining to the national phase entry into numerous markets of the PharmAla ALA and ABA molecule families and will provide a non-dilutive grant of approximately $35,000 to PharmAla to complete this work.
  • “We are pleased to be recognized as a worthy recipient of this grant funding from the Province of Ontario and IPON,” said Dr. Harpreet Kaur, VP of Research at PharmAla Biotech.
  • “As our drug discovery program continues to bear fruit, locking in valuable intellectual property remains a crucial and integral part of PharmAla’s long-term drug discovery program.

PharmAla Data to be Published in ACS Chemical Neuroscience

Retrieved on: 
Tuesday, February 20, 2024
MDXX, Research, OTC, Drug development, Patent, PCT, International Society, ACS Chemical Neuroscience, MDMA, Safety, University, Drug discovery, ISRP, Medicine, Pharmaceutical industry

It focuses on identifying key targets that are crucial for optimizing the safety and effectiveness of these compounds.

Key Points: 
  • It focuses on identifying key targets that are crucial for optimizing the safety and effectiveness of these compounds.
  • “PharmAla’s drug development program represents some of the world’s best work in the development of novel entactogenic molecules.
  • This research opens new avenues for developing innovative treatments in mental health care,” said Dr. Harpreet Kaur, VP of Research at PharmAla Biotech.
  • “Publication of our PCT filing for the P1 molecule should provide more context and information for potential drug development partners,” said Nick Kadysh, CEO, PharmAla Biotech.

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Retrieved on: 
Tuesday, February 20, 2024
Organic chemistry, Therapy, Bachelor of Science, Cancer, Alnylam Pharmaceuticals, Lakehead University, Senior, Enzyme, Doctor of Philosophy, Gene editing, Biotechnology, SAB, McGill University, Biocatalysis, Research and development, ANA, ECO, Masad, International Society, Oligonucleotide, Codexis, RNA, Nucleic acid, Central Waqf Council, Patient, Texas A&M University, About us, Infection, Editorial board, Publication, Development, Laboratory, Masad Damha, Management

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Key Points: 
  • This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.
  • “We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.
  • Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA).
  • Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne.

Children’s Hospital Los Angeles Neurologist Honored With Prestigious Research Award

Retrieved on: 
Monday, March 4, 2024
Mental Health, Research, Neurology, Hospitals, Genetics, Clinical Trials, Biometrics, Health, Science, Las Madrinas Ball, Division, Senior, Autism spectrum, Philosophy, CHLA, Boston, Multimedia, Scientist, Strategic planning, Disability studies, Tennis, International Society, Biomarker, DSM-IV codes, Abstract, USC, Yale University, Children's Hospital, Pediatrics, Diagnosis, Harvard Medical School, Child, Spectrum, Engineer, Medicine, Nursing

Children’s Hospital Los Angeles (CHLA) neurologist Shafali Spurling Jeste, MD , has been named the 2024 recipient of the prestigious Martha Bridge Denckla Award from the Child Neurology Society.

Key Points: 
  • Children’s Hospital Los Angeles (CHLA) neurologist Shafali Spurling Jeste, MD , has been named the 2024 recipient of the prestigious Martha Bridge Denckla Award from the Child Neurology Society.
  • View the full release here: https://www.businesswire.com/news/home/20240304251113/en/
    Children's Hospital Los Angeles Neurologist Shafali Spurling Jeste, MD, earns the Martha Bridge Denckla Award from the Child Neurology Society.
  • A Board-certified pediatric neurologist, Dr. Jeste has authored and contributed to more than 200 journal papers, editorials, chapters and abstracts.
  • She completed an internship, residency and a fellowship in behavioral child neurology at Boston Children’s Hospital.

Ceretype Neuromedicine Unveils Groundbreaking Methods to Quantify and Standardize Measures of Brain Activity at the 20th Annual Meeting of ISCTM

Retrieved on: 
Monday, March 4, 2024
Science, Neurology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Doctor of Philosophy, Neuropsychiatry, International Society, Central nervous system disease, Biomarker, CNS, Medicine, Poster, Magnetic resonance, MRI, Medical imaging

Ceretype Neuromedicine, a pioneer in practical application and integration of functional MRI (fMRI), presented new data at the 20th Annual Meeting of the International Society of CNS Clinical Trials and Methodology (ISCTM) in Washington DC on February 22nd.

Key Points: 
  • Ceretype Neuromedicine, a pioneer in practical application and integration of functional MRI (fMRI), presented new data at the 20th Annual Meeting of the International Society of CNS Clinical Trials and Methodology (ISCTM) in Washington DC on February 22nd.
  • The poster, entitled ‘Quantitative, Standardized Brain Network Activity Measures to Inform CNS Treatment Development,’ was presented by co-first author, Roni Setton, PhD and can be found here .
  • “We are pleased to share the groundbreaking methodological work on a novel quantitative imaging strategy,” said Ceretype CTO, Prantik Kundu, PhD.
  • “The findings highlight advances in the sensitivity and reliability of measured brain signal, demonstrating that a robust, standardized measure of brain network activity can be derived from fMRI.

UltraNav Transseptal System will present at "Best Interesting Case" at CRT

Retrieved on: 
Tuesday, March 5, 2024
Catheter, Multimedia, Physician, Cardiology, ICE, International Society, Electrophysiology, Safety, DIB, Anesthesia, Nursing, CRT, Patient, Journal, Heart, TEE, Learning

SCOTTSDALE, Ariz., March 5, 2024 /PRNewswire/ -- Franklin Mountain Medical announced today that the Dib UltraNav Transseptal Catheter System, which houses a needle and ultrasound in one system for use in transseptal procedures, including delivery of catheters to the left atrium without the need for TEE and anesthesia, will be featured throughout the 2024 Cardiovascular Research Technologies Meeting (CRT) next week, including as a "Best Interesting Case," at Innovations Hub, Mar. 10 9:43-9:51am ET and 10:55-11:10am ET; Best Interesting Case, Mar 10 2:12-2:20pm ET; and Valve and Structural Innovation Pipeline, Mar. 12, 10:47-10:55am ET.

Key Points: 
  • 10 9:43-9:51am ET and 10:55-11:10am ET; Best Interesting Case, Mar 10 2:12-2:20pm ET; and Valve and Structural Innovation Pipeline, Mar.
  • UltraNav improves the safety and accuracy of transseptal procedures by enabling better visualization of the catheter, needle, and needle tip.
  • Dr. Nabil Dib, founder of Dib UltraNav Medical and inventor of the UltraNav Transseptal Catheter System, will present at CRT.
  • His mission when developing the UltraNav system was to increase the safety and accuracy of structural transseptal heart procedures, which are on the increase.